Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells
Open Access
- 20 March 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Metabolomics
- Vol. 9 (5), 960-973
- https://doi.org/10.1007/s11306-013-0517-x
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cellsNature, 2012
- Metabolite Profiling Identifies a Key Role for Glycine in Rapid Cancer Cell ProliferationScience, 2012
- Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue – a GC-TOFMS based metabolomics studyBMC Genomics, 2012
- Cellular pharmacokinetic mechanisms of adriamycin resistance and its modulation by 20(S)‐ginsenoside Rh2 in MCF‐7/Adr cellsBritish Journal of Pharmacology, 2011
- Chronic Myeloid Leukemia Patients Sensitive and Resistant to Imatinib Treatment Show Different Metabolic ResponsesPLOS ONE, 2010
- Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cellsBritish Journal of Pharmacology, 2009
- MetaboAnalyst: a web server for metabolomic data analysis and interpretationNucleic Acids Research, 2009
- Metabolic signature of breast cancer cell line MCF-7: profiling of modified nucleosides via LC-IT MS couplingBMC Biochemistry, 2007
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochemical Pharmacology, 1999
- Cross-Validatory Estimation of the Number of Components in Factor and Principal Components ModelsTechnometrics, 1978